These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 28644773)

  • 1. Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide.
    Bashey A; Zhang MJ; McCurdy SR; St Martin A; Argall T; Anasetti C; Ciurea SO; Fasan O; Gaballa S; Hamadani M; Munshi P; Al Malki MM; Nakamura R; O'Donnell PV; Perales MA; Raj K; Romee R; Rowley S; Rocha V; Salit RB; Solh M; Soiffer RJ; Fuchs EJ; Eapen M
    J Clin Oncol; 2017 Sep; 35(26):3002-3009. PubMed ID: 28644773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study.
    Couban S; Aljurf M; Lachance S; Walker I; Toze C; Rubinger M; Lipton JH; Lee SJ; Szer J; Doocey R; Lewis ID; Huebsch L; Howson-Jan K; Lalancette M; Almohareb F; Chaudhri N; Ivison S; Broady R; Levings M; Fairclough D; Devins G; Szwajcer D; Foley R; Smith C; Panzarella T; Kerr H; Kariminia A; Schultz KR
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1410-1415. PubMed ID: 27154847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia.
    Nagler A; Dholaria B; Labopin M; Savani BN; Angelucci E; Koc Y; Arat M; Pioltelli P; Sica S; Gülbas Z; Tischer J; Bernasconi P; Pavlu J; Socié G; Blaise D; Rigacci L; Martino M; Diez-Martin JL; Perić Z; Giebel S; Mohty M
    Leukemia; 2020 Oct; 34(10):2766-2775. PubMed ID: 32393841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia.
    Nagler A; Labopin M; Dholaria B; Angelucci E; Afanasyev B; Cornelissen JJ; Sica S; Meijer E; Ciceri F; Van Gorkom G; Kröger N; Martin H; Pioltelli P; Risitano A; Canaani J; Savani BN; Sanz J; Mohty M
    Clin Cancer Res; 2021 Feb; 27(3):843-851. PubMed ID: 33148668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis.
    Yu X; Liu L; Xie Z; Dong C; Zhao L; Zhang J; Gu J; Zhu HH
    Crit Rev Oncol Hematol; 2019 Jan; 133():120-128. PubMed ID: 30661648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral Blood Stem Cells versus Bone Marrow for T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma.
    Mariotti J; Devillier R; Bramanti S; Giordano L; Sarina B; Furst S; Granata A; Maisano V; Pagliardini T; De Philippis C; Kogan M; Faucher C; Harbi S; Chabannon C; Carlo-Stella C; Bouabdallah R; Santoro A; Blaise D; Castagna L
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1810-1817. PubMed ID: 31128326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide.
    Mehta RS; Saliba RM; Alsfeld LC; Jorgensen JL; Wang SA; Anderlini P; Al-Atrash G; Bashir Q; Ciurea SO; Hosing CM; Im JS; Kebriaei P; Khouri I; Marin D; Nieto Y; Olson A; Oran B; Popat UR; Qazilbash MH; Ramdial J; Rondon G; Saini N; Srour SA; Rezvani K; Shpall EJ; Champlin RE; Alousi AM
    Transplant Cell Ther; 2021 Dec; 27(12):1003.e1-1003.e13. PubMed ID: 34537419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide.
    Castagna L; Crocchiolo R; Furst S; Bramanti S; El Cheikh J; Sarina B; Granata A; Mauro E; Faucher C; Mohty B; Harbi S; Chabannon C; Carlo-Stella C; Santoro A; Blaise D
    Biol Blood Marrow Transplant; 2014 May; 20(5):724-9. PubMed ID: 24530426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide.
    Ruggeri A; Labopin M; Bacigalupo A; Gülbas Z; Koc Y; Blaise D; Bruno B; Irrera G; Tischer J; Diez-Martin JL; Castagna L; Ciceri F; Mohty M; Nagler A
    Cancer; 2018 Apr; 124(7):1428-1437. PubMed ID: 29360162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis.
    Xu LP; Liu KY; Liu DH; Chen H; Han W; Chen YH; Wang Y; Huang XJ
    Bone Marrow Transplant; 2010 Jun; 45(6):985-92. PubMed ID: 19898505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral blood stem cell versus bone marrow graft for patients ≥60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Devillier R; Galimard JE; Blaise D; Raiola AM; Bramanti S; Grillo G; Pastano R; de Latour RP; Busca A; López-Corral L; Rodríguez AB; Schmid C; Forcade E; Vydra J; Solano C; Bug G; Neubauer A; Charbonnier A; Brissot E; Nagler A; Ciceri F; Mohty M
    Am J Hematol; 2024 Jul; 99(7):1250-1256. PubMed ID: 38778766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haploidentical bone marrow transplants for haematological malignancies using non-myeloablative conditioning therapy and post-transplant immunosuppression with cyclophosphamide: results from a single Australian centre.
    Bilmon IA; Kwan J; Gottlieb D; Kerridge I; McGurgan M; Huang G; George B; Hertzberg M; Bradstock KF
    Intern Med J; 2013 Feb; 43(2):191-6. PubMed ID: 22646924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
    van Besien K; Hari P; Zhang MJ; Liu HT; Stock W; Godley L; Odenike O; Larson R; Bishop M; Wickrema A; Gergis U; Mayer S; Shore T; Tsai S; Rhodes J; Cushing MM; Korman S; Artz A
    Haematologica; 2016 May; 101(5):634-43. PubMed ID: 26869630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T Cell-Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor Transplantation.
    Gorgeis J; Zhang X; Connor K; Brown S; Solomon SR; Morris LE; Holland HK; Bashey A; Solh M
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1861-1866. PubMed ID: 27375124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
    McCurdy SR; Kasamon YL; Kanakry CG; Bolaños-Meade J; Tsai HL; Showel MM; Kanakry JA; Symons HJ; Gojo I; Smith BD; Bettinotti MP; Matsui WH; Dezern AE; Huff CA; Borrello I; Pratz KW; Gladstone DE; Swinnen LJ; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
    Haematologica; 2017 Feb; 102(2):391-400. PubMed ID: 27846611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.
    Im A; Rashidi A; Wang T; Hemmer M; MacMillan ML; Pidala J; Jagasia M; Pavletic S; Majhail NS; Weisdorf D; Abdel-Azim H; Agrawal V; Al-Homsi AS; Aljurf M; Askar M; Auletta JJ; Bashey A; Beitinjaneh A; Bhatt VR; Byrne M; Cahn JY; Cairo M; Castillo P; Cerny J; Chhabra S; Choe H; Ciurea S; Daly A; Perez MAD; Farhadfar N; Gadalla SM; Gale R; Ganguly S; Gergis U; Hanna R; Hematti P; Herzig R; Hildebrandt GC; Lad DP; Lee C; Lehmann L; Lekakis L; Kamble RT; Kharfan-Dabaja MA; Khandelwal P; Martino R; Murthy HS; Nishihori T; O'Brien TA; Olsson RF; Patel SS; Perales MA; Prestidge T; Qayed M; Romee R; Schoemans H; Seo S; Sharma A; Solh M; Strair R; Teshima T; Urbano-Ispizua A; Van der Poel M; Vij R; Wagner JL; William B; Wirk B; Yared JA; Spellman SR; Arora M; Hamilton BK
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):1459-1468. PubMed ID: 32434056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors.
    Bradstock K; Bilmon I; Kwan J; Blyth E; Micklethwaite K; Huang G; Deren S; Byth K; Gottlieb D
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1641-5. PubMed ID: 26079442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2012 Dec; 18(12):1859-66. PubMed ID: 22863841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.